Literature DB >> 1331347

Postoperative venous thromboembolism and brain tumors: Part III. Biochemical profile.

R Sawaya1, R F Highsmith.   

Abstract

The plasminogen activator activity of 31 human brain tumor samples was assessed and the results correlated with clinical parameters and the postoperative occurrence of venous thrombosis. A significant negative correlation was found between plasminogen activator activity and venous thrombosis (P = 0.02), while positive correlations were observed between plasminogen activator activity and peritumoral brain edema (P = 0.03) and alpha 2 antiplasmin measured in the systemic circulation (P = 0.01). Tissue plasminogen activator was found in higher concentrations in meningioma tissue but did not correlate significantly with the occurrence of venous thrombosis. The results of this study suggest a local enzymatic degradation effect of plasminogen activator on thrombogenic substances present in the brain tumor and/or its environment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1331347     DOI: 10.1007/bf00177614

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  22 in total

1.  Exsistence and significance of a reflex-humoral antiplasmin system in the organism.

Authors:  B A KUDRJASHOV; T M KALISHEVSKA
Journal:  Nature       Date:  1963-05-25       Impact factor: 49.962

Review 2.  The role of the fibrinolytic system in thromboembolism.

Authors:  J G Vermylen; D A Chamone
Journal:  Prog Cardiovasc Dis       Date:  1979 Jan-Feb       Impact factor: 8.194

3.  Plasminogen activator activity and molecular weight patterns in human brain tumors.

Authors:  R Sawaya; R Highsmith
Journal:  J Neurosurg       Date:  1988-01       Impact factor: 5.115

4.  Activation of blood coagulation in cancer: Trousseau's syndrome revisited.

Authors:  F R Rickles; R L Edwards
Journal:  Blood       Date:  1983-07       Impact factor: 22.113

5.  Effect of optimization of hemodynamics on fibrinolytic activity and antithrombotic efficacy of external pneumatic calf compression.

Authors:  E W Salzman; G P McManama; A H Shapiro; L K Robertson; A S Donovan; H W Blume; J Sweeney; R D Kamm; M C Johnson; P M Black
Journal:  Ann Surg       Date:  1987-11       Impact factor: 12.969

6.  Brain surface exposure to CO2 and NdYag laser application: effect on pulmonary endothelium response in the rat.

Authors:  L Brizio-Molteni; M Quigley; L Cerullo; J Fitzsimons; N H Solliday; A Molteni
Journal:  Burns Incl Therm Inj       Date:  1987-02

7.  CNS influence on plasma levels of factor 8 activity.

Authors:  C G Gunn; J W Hampton
Journal:  Am J Physiol       Date:  1967-01

8.  The procoagulant factor of leukaemic promyelocytes: demonstration of immunologic cross reactivity with human brain tissue factor.

Authors:  M Gouault Heilmann; E Chardon; C Sultan; F Josso
Journal:  Br J Haematol       Date:  1975-06       Impact factor: 6.998

9.  Fibrinolytic shut-down after surgery: impairment of the balance between tissue-type plasminogen activator and its specific inhibitor.

Authors:  A D'Angelo; C Kluft; J H Verheijen; D C Rijken; E Mozzi; P M Mannucci
Journal:  Eur J Clin Invest       Date:  1985-12       Impact factor: 4.686

Review 10.  Hypercoagulation and thrombosis.

Authors:  J A Penner
Journal:  Med Clin North Am       Date:  1980-07       Impact factor: 5.456

View more
  9 in total

1.  [Supportive care and palliation in patients with malignant gliomas].

Authors:  Stefan Oberndorfer; Heinz Lahrmann
Journal:  Wien Med Wochenschr       Date:  2006-06

Review 2.  Medical management of patients with brain tumors.

Authors:  Patrick Y Wen; David Schiff; Santosh Kesari; Jan Drappatz; Debra C Gigas; Lisa Doherty
Journal:  J Neurooncol       Date:  2006-06-29       Impact factor: 4.130

3.  Risk factors for venous thromboembolism in patients undergoing craniotomy for neoplastic disease.

Authors:  Kristopher T Kimmell; Kevin A Walter
Journal:  J Neurooncol       Date:  2014-08-23       Impact factor: 4.130

4.  A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors.

Authors:  Michael B Streiff; Xiaobu Ye; Thomas S Kickler; Serena Desideri; Jayesh Jani; Joy Fisher; Stuart A Grossman
Journal:  J Neurooncol       Date:  2015-06-23       Impact factor: 4.130

5.  Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021.

Authors:  H Ian Robins; M Won; Wendy F Seiferheld; Christopher J Schultz; Ali K Choucair; David G Brachman; William F Demas; Minesh P Mehta
Journal:  Neuro Oncol       Date:  2006-01       Impact factor: 12.300

6.  Critically ill cancer patients are not consistently hypercoagulable after craniotomy.

Authors:  Joseph L Nates; Natarajan Aravindan; Cheryl Hirsch-Ginsberg; Kurt C Sizer; Spencer Kee; Anh T Nguyen; Karen Chen; Andrew D Shaw; Kristen J Price
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

7.  Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial.

Authors:  H Ian Robins; Anne O'Neill; Mark Gilbert; Mark Olsen; Ronald Sapiente; Brian Berkey; Minesh Mehta
Journal:  Cancer Chemother Pharmacol       Date:  2007-09-20       Impact factor: 3.333

Review 8.  Hemostatic changes in patients with brain tumors.

Authors:  L Thoron; E Arbit
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 9.  The management of thromboembolic disease in patients with central nervous system malignancies.

Authors:  Mary Ann Knovich; Glenn J Lesser
Journal:  Curr Treat Options Oncol       Date:  2004-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.